Class I · High risk
Dr. King's Natural Medicine Homeopathic Cold Sores & Herpes
Microbial contamination
FDA drug recalls in 2018
Every FDA drug recall initiated in 2018, newest first, with its risk class, status and the reason the FDA recorded. Use the cause and risk filters to narrow the year down.
1,681 recalls, newest first.
Class I · High risk
Dr. King's Natural Medicine Homeopathic Regional Allergies Rocky Mtns. U.S.
Microbial contamination
Class I · High risk
Dr. King's Natural Medicine Homeopathic Regional Allergies Northeastern U.S.
Microbial contamination
Class I · High risk
Dr. King's Natural Medicine Homeopathic Male Libido
Microbial contamination
Class I · High risk
Dr. King's Lymph Detox
Microbial contamination
Class I · High risk
Dr. King's aquaflora Candida High Potency
Microbial contamination
Class II · Moderate risk
AvKARE Valsartan and Hydrochlorothiazide 320 mg/25 mg tablets 90-count bottle
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Class II · Moderate risk
AvKARE Valsartan and Hydrochlorothiazide 320 mg/12.5 mg tablets
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Class II · Moderate risk
AvKARE Valsartan and Hydrochlorothiazide 160 mg/25 mg tablets
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Class II · Moderate risk
AvKARE Valsartan and Hydrochlorothiazide 160 mg/12.5 mg tablets
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Class II · Moderate risk
AvKARE Valsartan and Hydrochlorothiazide 80 mg/12.5 mg tablets
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Class II · Moderate risk
Valsartan
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Class II · Moderate risk
Valsartan
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Class II · Moderate risk
Valsartan HCTZ
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Class II · Moderate risk
Valsartan
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Class II · Moderate risk
Indomethacin Capsules
Failed Tablet/Capsule Specifications: customer complaints of deformed, clumped, misshaped, melted or stuck together capsules.
Class II · Moderate risk
Potassium Citrate Extended-Release Tablets
Failed Tablet/Capsule Specifications: Tablet breakage
Class II · Moderate risk
Potassium Citrate Extended-Release Tablets
Failed Tablet/Capsule Specifications: Tablet breakage
Class II · Moderate risk
Unit Dose Valsartan Tablets
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Class II · Moderate risk
Unit Dose Valsartan Tablets
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Class II · Moderate risk
Valsartan and Hydrochlorothiazide Tablets
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Class II · Moderate risk
Valsartan and Hydrochlorothiazide Tablets
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Class II · Moderate risk
Valsartan Tablets
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Class II · Moderate risk
Valsartan Tablets
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Class II · Moderate risk
Eyewash Purified water 98.3%
CGMP Deviations